Osteoporosis News and Research

Latest Osteoporosis News and Research

Aerobic exercise improves vascular reactivity to nearly normal levels

Pre-diabetic patients who engage in regular aerobic exercise improve their vascular reactivity to nearly normal levels, even if no weight loss is achieved, according to research presented today at the American Association of Clinical Endocrinologists (AACE) 21st Annual Meeting & Clinical Congress in Philadelphia. Pre-diabetes is a condition that affects nearly one in every four Americans.

28 May 2012

Intensive wellness program addresses multiple aspects of diabetes care

An integrated wellness team approach to diabetes care is helping patients lower their prescription costs and improve their condition, according to research presented today at the American Association of Clinical Endocrinologists' (AACE) 21st Annual Scientific & Clinical Congress in Philadelphia.

28 May 2012

Preoperative opportunity to control blood glucoses

Patients with diabetes mellitus experience significantly higher rates of surgical and systemic complications, higher mortality and increased length of stay during hospitalization following 11 major elective procedures, according to research presented today at the American Association of Clinical Endocrinologists (AACE) 21st Annual Meeting & Clinical Congress in Philadelphia.

28 May 2012

Medivir initiates MIV-711 phase I trial in bone disorders

Medivir AB, a research-based pharmaceutical company focused on infectious diseases, announced today that a phase I clinical trial has been initiated with its investigational drug, MIV-711, a cathepsin K inhibitor for the treatment of bone disorders characterized by excessive bone resorption such as osteoporosis, osteoarthritis and bone metastases.

28 May 2012

Women and men not receiving effective diagnostic testing and treatments for osteoporosis

Women and men are not receiving effective diagnostic testing and treatments of osteoporosis, a life threatening condition affecting millions of Americans, according to an expert today at the American Association of Clinical Endocrinologists (AACE) 21st Annual Meeting & Clinical Congress in Philadelphia.

28 May 2012

$IOF report predicts dramatic rise in osteoporosis-related fractures in Brazil$

IOF report predicts dramatic rise in osteoporosis-related fractures in Brazil

A new Audit report on fragility fractures, issued today by the International Osteoporosis Foundation (IOF), predicts that Brazil will experience an explosion in the number of fragility fractures due to osteoporosis in the coming decades.

25 May 2012

$Fragility fractures predicted to more than double in Latin America$

Fragility fractures predicted to more than double in Latin America

The International Osteoporosis Foundation (IOF), in cooperation with medical and patient societies from throughout Latin America, has today published a landmark report which compiles osteoporosis-related data on 14 countries and the region as a whole. The report shows that fragility fractures due to osteoporosis are predicted to more than double in some countries in the coming decades.

25 May 2012

Calcium supplements may increase the risk of heart attack

Calcium supplements might increase the risk of having a heart attack, and should be “taken with caution,” concludes research published in the online issue of the journal Heart.

24 May 2012

ACE’s Blood Sugar Basics Game Plan kicks off to help people with diabetes

The Blood Sugar Basics Game Plan, developed by the American College of Endocrinology (ACE), with support from Merck, is kicking off to help the nearly 26 million people in the U.S. who have diabetes find new ways to help manage their disease. Th

24 May 2012

Exercise can add years to a person's life

A recent study has shown that exercise can add years to a person's life. Still, as we age it can become more tedious and sometimes more difficult to exercise.

23 May 2012

Data from Alvine’s ALV003 Phase 2A trial on celiac disease presented at DDW 2012

Alvine Pharmaceuticals, Inc. today announced the presentation of data from a Phase 2A trial of its lead compound, ALV003, at the 2012 Digestive Diseases Week (DDW) meeting held in San Diego, California. The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The company plans to initiate a Phase 2B trial later this year.

23 May 2012

Salt intake: why is it bad for you?

Many of us are aware that we shouldn’t eat too much salt. To be precise, adults should avoid eating over 6g (or around about a teaspoon of salt) a day.

21 May 2012

Osteopenia/osteoporosis more prevalent among male patients with pulmonary disease

There is a very high prevalence of osteopenia/osteoporosis among male patients with pulmonary disease, according to a new study from researchers in California.

21 May 2012

Studies show vitamin D may benefit cardiovascular, skin and metabolic disorders

The Endocrine Society's new scientific statement published online today represents the first comprehensive evaluation of both the basic and clinical evidence related to the non-skeletal effects of vitamin D. The statement addresses current research regarding the associations of vitamin D with immune function, hypertension, stroke, skin conditions and maternal/fetal health.

19 May 2012

Personal genetic test results does not drive overuse of expensive medical care

People have increasing opportunities to participate in genetic testing that can indicate their range of risk for developing a disease. Receiving these results does not appreciably drive up or diminish test recipients' demand for potentially costly follow-up health services, according to a study performed by researchers at the National Institutes of Health and colleagues at other institutions.

19 May 2012

Personal genetic test results don't drive overuse of expensive medical care

People have more and more chances to participate in genetic testing that can indicate their range of risk for developing a disease. Receiving these results does not appreciably drive up- or diminish-test recipients' demand for potentially costly follow-up health services, according to a new study in the May 17, 2012 early online issue of Genetics in Medicine.

18 May 2012

Ono, Scil Proteins partner to discover and develop new Affilin therapeutics

Scil Proteins GmbH, a private biotech company specializing in the research, development and production of recombinant proteins, today announced that it has signed a collaboration agreement with Ono Pharmaceutical Co., Ltd., for the joint discovery and development of new Affilin therapeutics to treat various diseases.

15 May 2012

Genetic cause of rare genetic disorder, Hamamy syndrome

Scientists at A*STAR's Institute of Medical Biology (IMB), in collaboration with doctors and scientists in Jordan, Turkey, Switzerland and USA, have identified the genetic cause of a birth defect known as Hamamy syndrome .

14 May 2012

NBHA commends FDA for continuing investigation of bisphosphonate treatment for osteoporosis

In response to today's Perspective pieces published in the New England Journal Of Medicine, the National Bone Health Alliance (NBHA), a public-private partnership bringing together the expertise and resources of its 42 members from the private and non-profit sectors to collectively advance bone health and prevent disease, commends the U.S. Food and Drug Administration (FDA) for continuing to investigate the risks and benefits of long-term bisphosphonate treatment.

11 May 2012

$Women with spine fractures can benefit from alendronate therapy$

Women with spine fractures can benefit from alendronate therapy

Continuing a popular but controversial treatment for osteoporosis could reduce spine fracture risk for a particular group of patients, but others could see little to no change if they discontinue it. Based on available evidence, a UCSF researcher reevaluated his 2006 finding from a randomized 10-year study of alendronate, a type of bisphosphonate - a class of drugs that prevent loss of bone mass.

10 May 2012